170 related articles for article (PubMed ID: 21205921)
21. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
[TBL] [Abstract][Full Text] [Related]
22. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells.
Mori A; Lehmann S; O'Kelly J; Kumagai T; Desmond JC; Pervan M; McBride WH; Kizaki M; Koeffler HP
Cancer Res; 2006 Mar; 66(6):3222-9. PubMed ID: 16540674
[TBL] [Abstract][Full Text] [Related]
23. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
24. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
25. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
[TBL] [Abstract][Full Text] [Related]
26. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
[TBL] [Abstract][Full Text] [Related]
27. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
28. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
29. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
30. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
31. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
33. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
34. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
35. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo.
Hatzoglou A; Kampa M; Kogia C; Charalampopoulos I; Theodoropoulos PA; Anezinis P; Dambaki C; Papakonstanti EA; Stathopoulos EN; Stournaras C; Gravanis A; Castanas E
J Clin Endocrinol Metab; 2005 Feb; 90(2):893-903. PubMed ID: 15585562
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
Zaidman BZ; Wasser SP; Nevo E; Mahajna J
Int J Oncol; 2007 Oct; 31(4):959-67. PubMed ID: 17786330
[TBL] [Abstract][Full Text] [Related]
37. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
38. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
[TBL] [Abstract][Full Text] [Related]
39. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
40. The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line.
Kampa M; Papakonstanti EA; Alexaki VI; Hatzoglou A; Stournaras C; Castanas E
Exp Cell Res; 2004 Apr; 294(2):434-45. PubMed ID: 15023532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
